Essen BioScience to Screen Nycomed Drug Candidates | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Essen BioScience today said that it will provide ion channel screening services for Swiss drug firm Nycomed.

Ann Arbor, Mich.-based Essen said that the firms will collaborate on screening, optimizing, and developing modulators of voltage-gate ion channels for potential use as pain therapeutics. Essen said that it will contribute its expertise in ion channel drug discovery, planar array electrophysiology, and in vitro profiling.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.